Caleb S. Nerison
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Caleb S. Nerison has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed M. Raslan
Department of Neurological Surgery, Oregon Health & Science University, Portland, OR 97239, USA
3 shared publications Alexander Jessup
Scintillon Institute, San Diego, CA, United States
2 shared publications- Eric Halgren
Department of Radiology, University of California San Diego
2 shared publications - Jacob C. Garrett
Neurosciences Graduate Program, University of California
2 shared publications - Prakash Ambady
Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR, 97239, USA
2 shared publications - Sharona Ben-Haim
Department of Neurological Surgery, University of California, San Diego, La Jolla, CA, United States
2 shared publications
Latest Publications
- 1 June 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (6) , e191-e203
Opioidergic pain relief in humans is mediated by beta and high-gamma modulation in limbic regions
The neurophysiological mechanisms underlying opioid analgesia remain poorly understood, limiting progress toward nonaddictive alternatives. Fentanyl and hydromorphone were administered to patients experiencing semi-chronic, clinically relevant pain following surgical implantation of intracranial electrodes for seizure localization. Pooling recording sites by brain region, opioids significantly suppressed beta oscillations in ventral and dorsolateral prefrontal cortices and high-gamma amplitude in the insula, while enhancing both bands in the hippocampus and posterior cingulate. In an exploratory analysis, beta enhancement in the anterior hippocampus and high-gamma suppression in the insula accompanied pain relief in response to a constant dose. Under conservative modeling, ventral prefrontal beta suppression remained a robust predictor of analgesic efficacy in the sampled cohort. These findings bridge classical models of nociceptive gating with the elusive cerebral substrates that confer pain's distressing salience, identifying potential biomarkers for the development of nonaddictive opioid alternatives.
- 1 June 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (6) , e191-e203
Opioidergic pain relief in humans is mediated by beta and high-gamma modulation in limbic regions
The neurophysiological mechanisms underlying opioid analgesia remain poorly understood, limiting progress toward nonaddictive alternatives. Fentanyl and hydromorphone were administered to patients experiencing semi-chronic, clinically relevant pain following surgical implantation of intracranial electrodes for seizure localization. Pooling recording sites by brain region, opioids significantly suppressed beta oscillations in ventral and dorsolateral prefrontal cortices and high-gamma amplitude in the insula, while enhancing both bands in the hippocampus and posterior cingulate. In an exploratory analysis, beta enhancement in the anterior hippocampus and high-gamma suppression in the insula accompanied pain relief in response to a constant dose. Under conservative modeling, ventral prefrontal beta suppression remained a robust predictor of analgesic efficacy in the sampled cohort. These findings bridge classical models of nociceptive gating with the elusive cerebral substrates that confer pain's distressing salience, identifying potential biomarkers for the development of nonaddictive opioid alternatives.
- Open Access
Opioidergic pain relief in humans is mediated by beta and high-gamma modulation in limbic regions
The neurophysiological mechanisms underlying opioid analgesia remain poorly understood, limiting the development of non-addictive alternatives. Fentanyl and hydromorphone were administered to patients experiencing semi-chronic, clinically relevant pain following surgical implantation of intracranial electrodes for seizure localization. Opioids suppressed beta oscillations in lateral amygdala and ventral and dorsolateral prefrontal cortices, while increasing beta power in the medial amygdala and hippocampus. High-gamma amplitude was suppressed in the insula and lateral amygdala, and increased in the cingulate cortex and hippocampus. The magnitude of beta suppression in the ventral prefrontal cortex and beta enhancement in the medial amygdala and hippocampus, as well as high-gamma suppression in the insula, were positively correlated with pain relief in response to a constant dose. These findings identify electrophysiological events in a limbic network that may mediate opioidergic analgesia via nociceptive gating and reduced affective salience of pain, offering insights into the neural basis of pain relief and potential biomarkers for the development of non-addictive opioid alternatives.
Open AccessOpioidergic pain relief in humans is mediated by beta and high-gamma modulation in limbic regions
The neurophysiological mechanisms underlying opioid analgesia remain poorly understood, limiting the development of non-addictive alternatives. Fentanyl and hydromorphone were administered to patients experiencing semi-chronic, clinically relevant pain following surgical implantation of intracranial electrodes for seizure localization. Opioids suppressed beta oscillations in lateral amygdala and ventral and dorsolateral prefrontal cortices, while increasing beta power in the medial amygdala and hippocampus. High-gamma amplitude was suppressed in the insula and lateral amygdala, and increased in the cingulate cortex and hippocampus. The magnitude of beta suppression in the ventral prefrontal cortex and beta enhancement in the medial amygdala and hippocampus, as well as high-gamma suppression in the insula, were positively correlated with pain relief in response to a constant dose. These findings identify electrophysiological events in a limbic network that may mediate opioidergic analgesia via nociceptive gating and reduced affective salience of pain, offering insights into the neural basis of pain relief and potential biomarkers for the development of non-addictive opioid alternatives.
- Open Access
- 19 April 2023
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 9 (2)
Mismatch repair–deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome
Pathogenic mutations inMLH1,MSH2,PMS2, andMSH6compromise DNA mismatch repair mechanisms and in the heterozygous state result in Lynch syndrome, which is typified by a predisposition to endometrial, ovarian, colorectal, gastric, breast, hematologic, and soft tissue cancers. Rarely, germline pathogenic aberrations in these genes are associated with the development of primary central nervous system tumors. We present a report of an adult female with no prior cancer history who presented with a multicentric, infiltrative supratentorial glioma involving both the left anterior temporal horn and left precentral gyrus. Surgical treatment and neuropathological/molecular evaluation of these lesions revealed discordant isocitrate dehydrogenase (IDH) status and histologic grade at these spatially distinct disease sites. A frameshift alteration within theMLH1gene (p.R217fs*12, c.648delT) was identified in both lesions and subsequently identified in germline testing of a blood sample, consistent with Lynch syndrome. Despite distinct histopathologic features and divergent IDH status of the patient's tumors, the molecular findings suggest that both sites of intracranial neoplasia may have developed as a consequence of underlying monoallelic germline mismatch repair deficiency. This case illustrates the importance of characterizing the genetic profile of multicentric gliomas and highlights the oncogenic potential of germline mismatch repair gene pathogenic alterations within central nervous system gliomas.
- 19 April 2023
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 9 (2)
Open AccessMismatch repair–deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome
Pathogenic mutations inMLH1,MSH2,PMS2, andMSH6compromise DNA mismatch repair mechanisms and in the heterozygous state result in Lynch syndrome, which is typified by a predisposition to endometrial, ovarian, colorectal, gastric, breast, hematologic, and soft tissue cancers. Rarely, germline pathogenic aberrations in these genes are associated with the development of primary central nervous system tumors. We present a report of an adult female with no prior cancer history who presented with a multicentric, infiltrative supratentorial glioma involving both the left anterior temporal horn and left precentral gyrus. Surgical treatment and neuropathological/molecular evaluation of these lesions revealed discordant isocitrate dehydrogenase (IDH) status and histologic grade at these spatially distinct disease sites. A frameshift alteration within theMLH1gene (p.R217fs*12, c.648delT) was identified in both lesions and subsequently identified in germline testing of a blood sample, consistent with Lynch syndrome. Despite distinct histopathologic features and divergent IDH status of the patient's tumors, the molecular findings suggest that both sites of intracranial neoplasia may have developed as a consequence of underlying monoallelic germline mismatch repair deficiency. This case illustrates the importance of characterizing the genetic profile of multicentric gliomas and highlights the oncogenic potential of germline mismatch repair gene pathogenic alterations within central nervous system gliomas.
- Open Access
- 25 June 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 4 (1) , vdac104
Safety of intra-arterial chemotherapy with or without osmotic blood–brain barrier disruption for the treatment of patients with brain tumors
Intra-arterial administration of chemotherapy with or without osmotic blood–brain barrier disruption enhances delivery of therapeutic agents to brain tumors. The aim of this study is to evaluate the safety of these procedures. Retrospectively collected data from a prospective database of consecutive patients with primary and metastatic brain tumors who received intra-arterial chemotherapy without osmotic blood–brain barrier disruption (IA) or intra-arterial chemotherapy with osmotic blood–brain barrier disruption (IA/OBBBD) at Oregon Health and Science University (OHSU) between December 1997 and November 2018 is reported. Chemotherapy-related complications are detailed per Common Terminology Criteria for Adverse Events (CTCAE) guidelines. Procedure-related complications are grouped as major and minor. 4939 procedures (1102 IA; 3837 IA/OBBBD) were performed on 436 patients with various pathologies (primary central nervous system lymphoma [26.4%], glioblastoma [18.1%], and oligodendroglioma [14.7%]). Major procedure-related complications (IA: 12, 1%; IA/OBBBD: 27, 0.7%; P = .292) occurred in 39 procedures including 3 arterial dissections requiring intervention, 21 symptomatic strokes, 3 myocardial infarctions, 6 cervical cord injuries, and 6 deaths within 3 days. Minor procedure-related complications occurred in 330 procedures (IA: 41, 3.7%; IA/OBBBD: 289, 7.5%; P = .001). Chemotherapy-related complications with a CTCAE attribution and grade higher than 3 was seen in 359 (82.3%) patients. We provide safety and tolerability data from the largest cohort of consecutive patients who received IA or IA/OBBBD. Our data demonstrate that IA or IA/OBBBD safely enhance drug delivery to brain tumors and brain around the tumor.
- 25 June 2022
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 4 (1) , vdac104
Open AccessSafety of intra-arterial chemotherapy with or without osmotic blood–brain barrier disruption for the treatment of patients with brain tumors
Intra-arterial administration of chemotherapy with or without osmotic blood–brain barrier disruption enhances delivery of therapeutic agents to brain tumors. The aim of this study is to evaluate the safety of these procedures. Retrospectively collected data from a prospective database of consecutive patients with primary and metastatic brain tumors who received intra-arterial chemotherapy without osmotic blood–brain barrier disruption (IA) or intra-arterial chemotherapy with osmotic blood–brain barrier disruption (IA/OBBBD) at Oregon Health and Science University (OHSU) between December 1997 and November 2018 is reported. Chemotherapy-related complications are detailed per Common Terminology Criteria for Adverse Events (CTCAE) guidelines. Procedure-related complications are grouped as major and minor. 4939 procedures (1102 IA; 3837 IA/OBBBD) were performed on 436 patients with various pathologies (primary central nervous system lymphoma [26.4%], glioblastoma [18.1%], and oligodendroglioma [14.7%]). Major procedure-related complications (IA: 12, 1%; IA/OBBBD: 27, 0.7%; P = .292) occurred in 39 procedures including 3 arterial dissections requiring intervention, 21 symptomatic strokes, 3 myocardial infarctions, 6 cervical cord injuries, and 6 deaths within 3 days. Minor procedure-related complications occurred in 330 procedures (IA: 41, 3.7%; IA/OBBBD: 289, 7.5%; P = .001). Chemotherapy-related complications with a CTCAE attribution and grade higher than 3 was seen in 359 (82.3%) patients. We provide safety and tolerability data from the largest cohort of consecutive patients who received IA or IA/OBBBD. Our data demonstrate that IA or IA/OBBBD safely enhance drug delivery to brain tumors and brain around the tumor.